Depletion of circ_0007841 inhibits multiple myeloma development and BTZ resistance via miR-129-5p/JAG1 axis
Circular RNAs (circRNAs) possess important regulatory effects on multiple myeloma (MM) progression. Here, we aimed at exploring the function of circ_0007841 in MM and the underlying molecular mechanism. Expression of circ_0007841, microRNA (miR)-129-5p and Jagged1 (JAG1) was determined via qRT-PCR o...
Saved in:
| Published in | Cell cycle (Georgetown, Tex.) Vol. 19; no. 23; pp. 3289 - 3302 |
|---|---|
| Main Authors | , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Taylor & Francis
01.12.2020
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Circular RNAs (circRNAs) possess important regulatory effects on multiple myeloma (MM) progression. Here, we aimed at exploring the function of circ_0007841 in MM and the underlying molecular mechanism. Expression of circ_0007841, microRNA (miR)-129-5p and Jagged1 (JAG1) was determined via qRT-PCR or western blot assay. Methyl thiazolyl tetrazolium (MTT) assay was applied to examine cell viability and IC50 value of MM cells to bortezomib (BTZ). Colony formation assay was performed to analyze cell proliferation. Moreover, cell apoptosis was assessed by flow cytometry and western blot analysis. Cell metastasis was evaluated by wound healing assay and Transwell assay. Function of circ_0007841 in vivo was determined by xenograft tumor assay. Target relationship between miR-129-5p and circ_0007841 or JAG1 was confirmed via dual-luciferase reporter, RNA immunoprecipitation (RIP) and pull-down assays. The up-regulation of circ_0007841 and JAG1, and the down-regulation of miR-129-5p were detected in MM bone marrow aspirates and cells. Circ_0007841 knockdown significantly repressed cell proliferation, chemoresistance, and metastasis, while contributed to apoptosis of MM cells in vitro, and reduced tumor growth in vivo. Circ_0007841 targeted miR-129-5p, and miR-129-5p inhibition reversed impact of silencing of circ_0007841 on MM cells. JAG1 was a mRNA target of miR-129-5p, whose overexpression could undermine the miR-129-5p-mediated effects on MM cells. Circ_0007841 positively regulated JAG1 expression via absorbing miR-129-5p. Circ_0007841 knockdown inhibited MM cell proliferation, metastasis and chemoresistance through modulating miR-129-5p/JAG1 axis, suggesting that circ_0007841 might serve as a potential therapeutic target of MM. |
|---|---|
| AbstractList | Circular RNAs (circRNAs) possess important regulatory effects on multiple myeloma (MM) progression. Here, we aimed at exploring the function of circ_0007841 in MM and the underlying molecular mechanism. Expression of circ_0007841, microRNA (miR)-129-5p and Jagged1 (JAG1) was determined via qRT-PCR or western blot assay. Methyl thiazolyl tetrazolium (MTT) assay was applied to examine cell viability and IC50 value of MM cells to bortezomib (BTZ). Colony formation assay was performed to analyze cell proliferation. Moreover, cell apoptosis was assessed by flow cytometry and western blot analysis. Cell metastasis was evaluated by wound healing assay and Transwell assay. Function of circ_0007841
was determined by xenograft tumor assay. Target relationship between miR-129-5p and circ_0007841 or JAG1 was confirmed via dual-luciferase reporter, RNA immunoprecipitation (RIP) and pull-down assays. The up-regulation of circ_0007841 and JAG1, and the down-regulation of miR-129-5p were detected in MM bone marrow aspirates and cells. Circ_0007841 knockdown significantly repressed cell proliferation, chemoresistance, and metastasis, while contributed to apoptosis of MM cells
, and reduced tumor growth
. Circ_0007841 targeted miR-129-5p, and miR-129-5p inhibition reversed impact of silencing of circ_0007841 on MM cells. JAG1 was a mRNA target of miR-129-5p, whose overexpression could undermine the miR-129-5p-mediated effects on MM cells. Circ_0007841 positively regulated JAG1 expression via absorbing miR-129-5p. Circ_0007841 knockdown inhibited MM cell proliferation, metastasis and chemoresistance through modulating miR-129-5p/JAG1 axis, suggesting that circ_0007841 might serve as a potential therapeutic target of MM. Circular RNAs (circRNAs) possess important regulatory effects on multiple myeloma (MM) progression. Here, we aimed at exploring the function of circ_0007841 in MM and the underlying molecular mechanism. Expression of circ_0007841, microRNA (miR)-129-5p and Jagged1 (JAG1) was determined via qRT-PCR or western blot assay. Methyl thiazolyl tetrazolium (MTT) assay was applied to examine cell viability and IC50 value of MM cells to bortezomib (BTZ). Colony formation assay was performed to analyze cell proliferation. Moreover, cell apoptosis was assessed by flow cytometry and western blot analysis. Cell metastasis was evaluated by wound healing assay and Transwell assay. Function of circ_0007841 in vivo was determined by xenograft tumor assay. Target relationship between miR-129-5p and circ_0007841 or JAG1 was confirmed via dual-luciferase reporter, RNA immunoprecipitation (RIP) and pull-down assays. The up-regulation of circ_0007841 and JAG1, and the down-regulation of miR-129-5p were detected in MM bone marrow aspirates and cells. Circ_0007841 knockdown significantly repressed cell proliferation, chemoresistance, and metastasis, while contributed to apoptosis of MM cells in vitro, and reduced tumor growth in vivo. Circ_0007841 targeted miR-129-5p, and miR-129-5p inhibition reversed impact of silencing of circ_0007841 on MM cells. JAG1 was a mRNA target of miR-129-5p, whose overexpression could undermine the miR-129-5p-mediated effects on MM cells. Circ_0007841 positively regulated JAG1 expression via absorbing miR-129-5p. Circ_0007841 knockdown inhibited MM cell proliferation, metastasis and chemoresistance through modulating miR-129-5p/JAG1 axis, suggesting that circ_0007841 might serve as a potential therapeutic target of MM. Circular RNAs (circRNAs) possess important regulatory effects on multiple myeloma (MM) progression. Here, we aimed at exploring the function of circ_0007841 in MM and the underlying molecular mechanism. Expression of circ_0007841, microRNA (miR)-129-5p and Jagged1 (JAG1) was determined via qRT-PCR or western blot assay. Methyl thiazolyl tetrazolium (MTT) assay was applied to examine cell viability and IC50 value of MM cells to bortezomib (BTZ). Colony formation assay was performed to analyze cell proliferation. Moreover, cell apoptosis was assessed by flow cytometry and western blot analysis. Cell metastasis was evaluated by wound healing assay and Transwell assay. Function of circ_0007841 in vivo was determined by xenograft tumor assay. Target relationship between miR-129-5p and circ_0007841 or JAG1 was confirmed via dual-luciferase reporter, RNA immunoprecipitation (RIP) and pull-down assays. The up-regulation of circ_0007841 and JAG1, and the down-regulation of miR-129-5p were detected in MM bone marrow aspirates and cells. Circ_0007841 knockdown significantly repressed cell proliferation, chemoresistance, and metastasis, while contributed to apoptosis of MM cells in vitro , and reduced tumor growth in vivo . Circ_0007841 targeted miR-129-5p, and miR-129-5p inhibition reversed impact of silencing of circ_0007841 on MM cells. JAG1 was a mRNA target of miR-129-5p, whose overexpression could undermine the miR-129-5p-mediated effects on MM cells. Circ_0007841 positively regulated JAG1 expression via absorbing miR-129-5p. Circ_0007841 knockdown inhibited MM cell proliferation, metastasis and chemoresistance through modulating miR-129-5p/JAG1 axis, suggesting that circ_0007841 might serve as a potential therapeutic target of MM. Circular RNAs (circRNAs) possess important regulatory effects on multiple myeloma (MM) progression. Here, we aimed at exploring the function of circ_0007841 in MM and the underlying molecular mechanism. Expression of circ_0007841, microRNA (miR)-129-5p and Jagged1 (JAG1) was determined via qRT-PCR or western blot assay. Methyl thiazolyl tetrazolium (MTT) assay was applied to examine cell viability and IC50 value of MM cells to bortezomib (BTZ). Colony formation assay was performed to analyze cell proliferation. Moreover, cell apoptosis was assessed by flow cytometry and western blot analysis. Cell metastasis was evaluated by wound healing assay and Transwell assay. Function of circ_0007841 in vivo was determined by xenograft tumor assay. Target relationship between miR-129-5p and circ_0007841 or JAG1 was confirmed via dual-luciferase reporter, RNA immunoprecipitation (RIP) and pull-down assays. The up-regulation of circ_0007841 and JAG1, and the down-regulation of miR-129-5p were detected in MM bone marrow aspirates and cells. Circ_0007841 knockdown significantly repressed cell proliferation, chemoresistance, and metastasis, while contributed to apoptosis of MM cells in vitro, and reduced tumor growth in vivo. Circ_0007841 targeted miR-129-5p, and miR-129-5p inhibition reversed impact of silencing of circ_0007841 on MM cells. JAG1 was a mRNA target of miR-129-5p, whose overexpression could undermine the miR-129-5p-mediated effects on MM cells. Circ_0007841 positively regulated JAG1 expression via absorbing miR-129-5p. Circ_0007841 knockdown inhibited MM cell proliferation, metastasis and chemoresistance through modulating miR-129-5p/JAG1 axis, suggesting that circ_0007841 might serve as a potential therapeutic target of MM.Circular RNAs (circRNAs) possess important regulatory effects on multiple myeloma (MM) progression. Here, we aimed at exploring the function of circ_0007841 in MM and the underlying molecular mechanism. Expression of circ_0007841, microRNA (miR)-129-5p and Jagged1 (JAG1) was determined via qRT-PCR or western blot assay. Methyl thiazolyl tetrazolium (MTT) assay was applied to examine cell viability and IC50 value of MM cells to bortezomib (BTZ). Colony formation assay was performed to analyze cell proliferation. Moreover, cell apoptosis was assessed by flow cytometry and western blot analysis. Cell metastasis was evaluated by wound healing assay and Transwell assay. Function of circ_0007841 in vivo was determined by xenograft tumor assay. Target relationship between miR-129-5p and circ_0007841 or JAG1 was confirmed via dual-luciferase reporter, RNA immunoprecipitation (RIP) and pull-down assays. The up-regulation of circ_0007841 and JAG1, and the down-regulation of miR-129-5p were detected in MM bone marrow aspirates and cells. Circ_0007841 knockdown significantly repressed cell proliferation, chemoresistance, and metastasis, while contributed to apoptosis of MM cells in vitro, and reduced tumor growth in vivo. Circ_0007841 targeted miR-129-5p, and miR-129-5p inhibition reversed impact of silencing of circ_0007841 on MM cells. JAG1 was a mRNA target of miR-129-5p, whose overexpression could undermine the miR-129-5p-mediated effects on MM cells. Circ_0007841 positively regulated JAG1 expression via absorbing miR-129-5p. Circ_0007841 knockdown inhibited MM cell proliferation, metastasis and chemoresistance through modulating miR-129-5p/JAG1 axis, suggesting that circ_0007841 might serve as a potential therapeutic target of MM. |
| Author | Lin, Quande Ma, Ruojin Song, Chunge Wang, Yan Li, Xiaojie |
| Author_xml | – sequence: 1 givenname: Yan surname: Wang fullname: Wang, Yan email: wy1782@126.com organization: The Fifth Affiliated Hospital of Zhengzhou University – sequence: 2 givenname: Quande surname: Lin fullname: Lin, Quande organization: Henan Cancer Hospital – sequence: 3 givenname: Chunge surname: Song fullname: Song, Chunge organization: The Fifth Affiliated Hospital of Zhengzhou University – sequence: 4 givenname: Ruojin surname: Ma fullname: Ma, Ruojin organization: The Fifth Affiliated Hospital of Zhengzhou University – sequence: 5 givenname: Xiaojie surname: Li fullname: Li, Xiaojie organization: The Fifth Affiliated Hospital of Zhengzhou University |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33131409$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFUcluFDEQtVAQWeATQD5y6cTr2C0kRAhZiCIhoXDhYrndNjG47Y7dMzB_H7dmBkEOcKpS-S3leodgL6ZoAXiJ0TFGEp1gTiXDCB8TROpI0lYg_AQcYM5xwxDie3NPZTOD9sFhKd8RIlK0-BnYpxRTzFB7AH58sGOwk08RJgeNz0YhhESVhj7e-c5PBQ7LMPmKgsPahjRo2NtVbcbBxgnq2MP3t19htsWXSUdj4cprOPjPDSZtw8eT69NLDPUvX56Dp06HYl9s6xH4cnF-e3bV3Hy6_Hh2etMYTtnUtBK1rmNUUKZlZ3j9l2b9AjkimHE9sW3fW-SolMLJjgjDOmpJaxzTrDMtokfg7UZ3XHaD7U1dM-ugxuwHndcqaa_-fon-Tn1LKyUExwshq8DrrUBO90tbJjX4YmwIOtq0LIowvpB8QfDs9epPr98muwtXwJsNwORUSrZOGT_p-eDV2geFkZrzVLs81Zyn2uZZ2fwRe2fwP967Dc9Hl_Kgf6YcejXpdUjZ5ZqSL4r-W-IBZfO1xA |
| CitedBy_id | crossref_primary_10_3389_fonc_2022_868363 crossref_primary_10_2217_bmm_2022_0349 crossref_primary_10_1016_j_prp_2022_154129 crossref_primary_10_18632_aging_202911 crossref_primary_10_37349_etat_2021_00057 crossref_primary_10_2485_jhtb_30_257 crossref_primary_10_1177_15330338241285149 crossref_primary_10_3389_fgene_2023_1320185 crossref_primary_10_1016_j_jds_2022_06_012 crossref_primary_10_3390_cancers16010084 crossref_primary_10_1016_j_jbo_2021_100381 crossref_primary_10_1007_s12033_022_00618_6 crossref_primary_10_1631_jzus_B2200211 crossref_primary_10_1016_j_trim_2024_102165 crossref_primary_10_3390_ijms232012628 crossref_primary_10_1007_s11033_022_07668_8 crossref_primary_10_3389_fonc_2022_900374 crossref_primary_10_1016_j_exphem_2024_104709 crossref_primary_10_1016_j_ncrna_2024_09_006 crossref_primary_10_1186_s12935_023_03187_z crossref_primary_10_1016_j_biopha_2024_117027 crossref_primary_10_1177_15330338231202391 crossref_primary_10_3390_cancers14071700 crossref_primary_10_1097_CAD_0000000000001166 crossref_primary_10_1097_CAD_0000000000001243 crossref_primary_10_1007_s11845_023_03410_w crossref_primary_10_1155_2022_8330659 crossref_primary_10_1016_j_leukres_2021_106774 crossref_primary_10_1016_j_ejphar_2022_175380 crossref_primary_10_1007_s00432_023_05317_6 crossref_primary_10_1080_1120009X_2022_2056995 crossref_primary_10_1016_j_jphs_2022_01_013 crossref_primary_10_1097_CAD_0000000000001348 |
| Cites_doi | 10.1093/bioinformatics/btu257 10.1177/1533033820928371 10.1111/jcmm.15035 10.1093/nar/gkl151 10.18632/oncotarget.22846 10.7150/ijbs.27523 10.3390/cancers12020449 10.1007/s13577-019-00276-y 10.1093/annonc/mdq370 10.1016/j.gene.2015.10.065 10.1186/s12935-020-01475-6 10.1080/17474086.2018.1517041 10.1186/s13046-019-1071-9 10.1016/j.biopha.2018.05.123 10.1055/a-0639-5742 10.1158/1078-0432.CCR-11-2371 10.1186/s12885-020-6515-2 10.1200/EDBK_159009 10.1016/j.biopha.2018.05.105 10.3390/antiox9040307 10.1056/NEJMra1011442 10.3389/fmolb.2020.00109 10.1016/j.prp.2018.07.025 10.3389/fonc.2019.01261 10.1080/16078454.2019.1669924 10.1242/dev.102.4.837 10.1158/0008-5472.CAN-05-1069 10.1111/joim.12590 10.2147/CMAR.S241089 10.1002/kjm2.12057 10.1158/1078-0432.CCR-14-1437 10.1038/s41419-018-0343-1 10.1016/j.canlet.2018.01.011 10.1038/s41408-017-0001-3 10.1016/j.blre.2018.11.003 10.1186/s12943-018-0934-6 10.1146/annurev-med-112017-091045 10.1002/jcp.26425 10.1002/jcp.26383 10.1038/nature11993 10.1080/15384101.2020.1711578 10.1016/j.molonc.2012.09.006 |
| ContentType | Journal Article |
| Copyright | 2020 Informa UK Limited, trading as Taylor & Francis Group 2020 2020 Informa UK Limited, trading as Taylor & Francis Group 2020 Informa UK Limited, trading as Taylor & Francis Group |
| Copyright_xml | – notice: 2020 Informa UK Limited, trading as Taylor & Francis Group 2020 – notice: 2020 Informa UK Limited, trading as Taylor & Francis Group 2020 Informa UK Limited, trading as Taylor & Francis Group |
| DBID | AAYXX CITATION NPM 7X8 5PM |
| DOI | 10.1080/15384101.2020.1839701 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| DocumentTitleAlternate | Y. WANG ET AL |
| EISSN | 1551-4005 |
| EndPage | 3302 |
| ExternalDocumentID | PMC7751678 33131409 10_1080_15384101_2020_1839701 1839701 |
| Genre | Research Article Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- 0BK 0R~ 29B 30N 4.4 53G 5GY AAHBH AAJMT AALDU AAMIU AAPUL AAQRR ABCCY ABFIM ABJNI ABLIJ ABPAQ ABPEM ABTAI ABXUL ABXYU ACGFS ACTIO ADBBV ADCVX ADGTB AEISY AENEX AEXWM AEYOC AGDLA AHDZW AIJEM AKBVH AKOOK ALMA_UNASSIGNED_HOLDINGS ALQZU AOIJS AQRUH AVBZW AWYRJ BAWUL BLEHA CCCUG DGEBU DIK DKSSO E3Z EBS EJD EMOBN F5P GTTXZ H13 HYE IPNFZ KRBQP KWAYT KYCEM LJTGL M4Z O9- OK1 P2P RIG RNANH ROSJB RPM RTWRZ SJN SNACF TBQAZ TDBHL TEI TFL TFT TFW TQWBC TR2 TTHFI TUROJ ZGOLN AAGDL AAHIA AAYXX ADYSH AFRVT AIYEW AMPGV CITATION AAGME ABFMO ACDHJ ACZPZ ADOPC AURDB BFWEY C1A CWRZV NPM PCLFJ 7X8 5PM TASJS |
| ID | FETCH-LOGICAL-c534t-9809fb43734a8bc5701a4d60f274cfd2e9dde0f3887f8b27c4b3e29cf4a4bc903 |
| ISSN | 1538-4101 1551-4005 |
| IngestDate | Thu Aug 21 14:11:25 EDT 2025 Fri Jul 11 02:43:44 EDT 2025 Thu Apr 03 06:59:10 EDT 2025 Thu Apr 24 23:11:45 EDT 2025 Tue Jul 01 02:01:18 EDT 2025 Wed Dec 25 09:04:46 EST 2024 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 23 |
| Keywords | chemoresistance JAG1 proliferation metastasis Multiple myeloma circ_0007841 miR-129-5p |
| Language | English |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c534t-9809fb43734a8bc5701a4d60f274cfd2e9dde0f3887f8b27c4b3e29cf4a4bc903 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://www.tandfonline.com/doi/pdf/10.1080/15384101.2020.1839701?needAccess=true |
| PMID | 33131409 |
| PQID | 2456856210 |
| PQPubID | 23479 |
| PageCount | 14 |
| ParticipantIDs | proquest_miscellaneous_2456856210 crossref_citationtrail_10_1080_15384101_2020_1839701 pubmedcentral_primary_oai_pubmedcentral_nih_gov_7751678 pubmed_primary_33131409 informaworld_taylorfrancis_310_1080_15384101_2020_1839701 crossref_primary_10_1080_15384101_2020_1839701 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2020-12-01 |
| PublicationDateYYYYMMDD | 2020-12-01 |
| PublicationDate_xml | – month: 12 year: 2020 text: 2020-12-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Cell cycle (Georgetown, Tex.) |
| PublicationTitleAlternate | Cell Cycle |
| PublicationYear | 2020 |
| Publisher | Taylor & Francis |
| Publisher_xml | – name: Taylor & Francis |
| References | cit0011 cit0033 cit0012 cit0034 cit0031 cit0010 cit0032 cit0030 Xin Z (cit0041) 2017; 16 Nie WB (cit0008) 2018; 22 cit0019 cit0017 cit0039 cit0018 cit0015 cit0037 cit0016 cit0038 cit0013 cit0035 cit0014 cit0036 cit0022 cit0044 cit0001 cit0023 cit0020 cit0042 cit0021 cit0043 cit0040 cit0009 cit0006 cit0028 cit0007 cit0029 cit0004 cit0026 cit0005 cit0027 cit0002 cit0024 cit0003 cit0025 |
| References_xml | – ident: cit0033 doi: 10.1093/bioinformatics/btu257 – ident: cit0032 doi: 10.1177/1533033820928371 – ident: cit0019 doi: 10.1111/jcmm.15035 – ident: cit0026 doi: 10.1093/nar/gkl151 – ident: cit0011 doi: 10.18632/oncotarget.22846 – volume: 16 start-page: 80 year: 2017 ident: cit0041 publication-title: Brief Funct Genomics – ident: cit0009 doi: 10.7150/ijbs.27523 – ident: cit0035 doi: 10.3390/cancers12020449 – ident: cit0016 doi: 10.1007/s13577-019-00276-y – ident: cit0003 doi: 10.1093/annonc/mdq370 – ident: cit0020 doi: 10.1016/j.gene.2015.10.065 – ident: cit0031 doi: 10.1186/s12935-020-01475-6 – ident: cit0018 doi: 10.1080/17474086.2018.1517041 – volume: 22 start-page: 6239 year: 2018 ident: cit0008 publication-title: Eur Rev Med Pharmacol Sci – ident: cit0012 doi: 10.1186/s13046-019-1071-9 – ident: cit0038 doi: 10.1016/j.biopha.2018.05.123 – ident: cit0004 doi: 10.1055/a-0639-5742 – ident: cit0022 doi: 10.1158/1078-0432.CCR-11-2371 – ident: cit0030 doi: 10.1186/s12885-020-6515-2 – ident: cit0024 doi: 10.1200/EDBK_159009 – ident: cit0039 doi: 10.1016/j.biopha.2018.05.105 – ident: cit0043 doi: 10.3390/antiox9040307 – ident: cit0001 doi: 10.1056/NEJMra1011442 – ident: cit0029 doi: 10.3389/fmolb.2020.00109 – ident: cit0042 doi: 10.1016/j.prp.2018.07.025 – ident: cit0013 doi: 10.3389/fonc.2019.01261 – ident: cit0028 doi: 10.1080/16078454.2019.1669924 – ident: cit0027 doi: 10.1242/dev.102.4.837 – ident: cit0021 doi: 10.1158/0008-5472.CAN-05-1069 – ident: cit0005 doi: 10.1111/joim.12590 – ident: cit0010 doi: 10.2147/CMAR.S241089 – ident: cit0015 doi: 10.1002/kjm2.12057 – ident: cit0017 doi: 10.1158/1078-0432.CCR-14-1437 – ident: cit0036 doi: 10.1038/s41419-018-0343-1 – ident: cit0007 doi: 10.1016/j.canlet.2018.01.011 – ident: cit0023 doi: 10.1038/s41408-017-0001-3 – ident: cit0002 doi: 10.1016/j.blre.2018.11.003 – ident: cit0006 doi: 10.1186/s12943-018-0934-6 – ident: cit0025 doi: 10.1146/annurev-med-112017-091045 – ident: cit0040 doi: 10.1002/jcp.26425 – ident: cit0037 doi: 10.1002/jcp.26383 – ident: cit0034 doi: 10.1038/nature11993 – ident: cit0044 doi: 10.1080/15384101.2020.1711578 – ident: cit0014 doi: 10.1016/j.molonc.2012.09.006 |
| SSID | ssj0028791 |
| Score | 2.4780233 |
| Snippet | Circular RNAs (circRNAs) possess important regulatory effects on multiple myeloma (MM) progression. Here, we aimed at exploring the function of circ_0007841 in... |
| SourceID | pubmedcentral proquest pubmed crossref informaworld |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 3289 |
| SubjectTerms | chemoresistance circ_0007841 JAG1 metastasis miR-129-5p Multiple myeloma proliferation Research Paper |
| Title | Depletion of circ_0007841 inhibits multiple myeloma development and BTZ resistance via miR-129-5p/JAG1 axis |
| URI | https://www.tandfonline.com/doi/abs/10.1080/15384101.2020.1839701 https://www.ncbi.nlm.nih.gov/pubmed/33131409 https://www.proquest.com/docview/2456856210 https://pubmed.ncbi.nlm.nih.gov/PMC7751678 |
| Volume | 19 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELdKJ9BeJr7p-JCReKvSJbGTOI-lAyokkECdNvYSJU6yBta02hrU8tdzFzupC0UDXqIoie0ov1_Od-fzHSGvbBbEjKeelQYCDJRU2lacxKnlMN8B7Txx03oF_8NHf3zC3595Z53OyohaqpbJQP7Yua_kf1CFa4Ar7pL9B2TbTuECnAO-cASE4fhXGB9nC8ydrVQ-WVzJqJ6MudMvymmR4JpAGzA4W2eX81nc7JJqY8tfT877YHKjGon_-Pci7s-KzxZM0Ja3wALOw3dOP14V16YaO0KPn1zD69RuBuVX1_b8JFsNDP_CqXZIfzGCf1Tegk8VOrBbF4-ODR5Nq_LCCMitOVDNv-oM4dpB4ZrBHpkWqh7aqba3JXVDg10uM2Qoc1VRod-Eu4qGRBHNQZAMcKwBKniBGs0AfDGrEWfMYZjQazPXtRGIza1bZM8FA8Ptkr3h-Pj8tDXWRRA6zY4vYR_tHHWf3Gn62VJrtpLe7jJdfo3ANVSayV1yoG0ROlTEukc6WXmf3FbVSdcPyLeWXnSeU5NetKEXbehFNb2oQS8K8FKgF93QiwK96IZeR0guiuR6SE7evpmMxpauzWFJj_GlFQo7zBPMi8VjkUgPvkbMU9_O3YDLPHWzEOZNO2cwh-UicQPJE5a5ocx5zBMZ2uwR6ZbzMntCqI0p13zhc8FyzoQXYyFbeBxUWxkmwu8R3nzaSOrE9Vg_5TJydH7bBpwIwYk0OD0yaJstVOaWmxqEJm7RsnaZ5aq-TcRuaPuyATkC-YyLbnGZzavrCAMLBBgZjt0jjxXo7es05OmRYIsO7QOY-337TllM6xzwQeA5oGce_rHPp2R_8zM-I93lVZU9B_15mbzQVP8Jkh64jw |
| linkProvider | Library Specific Holdings |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELZQEYJLebfL00hcs01iJ3aObaEspd0D2koVF8t2bDVqN1ntZhHl1zOTx7JbgXroNc5EY2fG_sYef0PIx5AJzXieBLmQEKDkNgy00XkQsTQCdG7ivDnBPx2nozN-fJ6cr92FwbRKjKF9SxTRzNXo3LgZ3afE7aGXcrAlCO9ieARrvMArXPeTLBVYxYCF41XQJUXWcabKAGX6Wzz_-8zG-rTBXvovDHozlXJtbTp6TGzfqzYl5XK4rM3Q_r5B-Hi3bj8h2x10pfutrT0l91z5jDxoi1lePyeXn9wMmbyrklae2mJuVQMNeESL8qIwRb2gffoinV67q2qqaf43Z4mCYvRg8oPO3QJBLVgj_VloOi2-BwAXgmS2d7z_JaL6V7F4Qc6OPk8OR0FXyiGwCeN1kMkw8wZplLiWxiaguOZ5GnoIiq3PY5fBNBt6BlOelyYWlhvm4sx6rrmxWchekq2yKt0uoSEydKUy5ZJ5zmSise4pvA5IyGZGpgPC-x-obMdzjuU2rlTU0aH246hwHFU3jgMyXInNWqKP2wSydetQdbPD4ttyKIrdIvuhNyUF7oxnNLp01XKh8BxaAiaNwgHZaU1rpQ5jEUN-sgERG0a3egGpwjdbyuKioQwXIokAlry6g87vycPR5PREnXwdf3tNHmFTm9bzhmzV86V7C-CsNu8a7_sDUR0njw |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELZQEYhLecOWAkbi6q0TO4lzLC1LKbBCqJUQF8uPWI3aTVbdLKL8embyWLoVqIdeY080dmbsb-LxN4S85SIzQvqE-UxBgOIdZ8YazyKRRoDObezbE_wv0_TgWB5-T4ZswkWfVokxdOiIItq1Gp177sOQEbeDTirBlCC6i-ERbPEZ3uC6nSJ5ON7i4NNVzKWyvKdMVQxlhks8_3vN2va0Rl76Lwh6NZPy0tY0uU_sMKguI-V0vGzs2P2-wvd4o1E_IJs9cKW7naU9JLeK6hG505WyvHhMTveLOfJ41xWtA3XludMtMJARLauT0pbNgg7Ji3R2UZzVM0P934wlCnrRd0c_KIT_CGnBFunP0tBZ-Y0BWGDJfOdw90NEza9y8YQcT94f7R2wvpADc4mQDcsVz4NFEiVplHUJKG6kT3mAkNgFHxc5LLI8CFjwgrJx5qQVRZy7II20LufiKdmo6qp4TihHfq5UpVKJIIVKDFY9he6Ag1xuVToicvh-2vUs51hs40xHPRnqMI8a51H38zgi45XYvKP5uE4gv2wcumn_r4SuGIoW18i-GSxJgzPjCY2pinq50HgKrQCRRnxEnnWWtVJHiEggO9mIZGs2t-qAROHrLVV50hKGZ1kSASjZuoHOr8ndr_sT_fnj9NMLcg9bupyebbLRnC-Ll4DMGvuq9b0_fD8mMw |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Depletion+of+circ_0007841+inhibits+multiple+myeloma+development+and+BTZ+resistance+via+miR-129-5p%2FJAG1+axis&rft.jtitle=Cell+cycle+%28Georgetown%2C+Tex.%29&rft.au=Wang%2C+Yan&rft.au=Lin%2C+Quande&rft.au=Song%2C+Chunge&rft.au=Ma%2C+Ruojin&rft.date=2020-12-01&rft.eissn=1551-4005&rft.volume=19&rft.issue=23&rft.spage=3289&rft_id=info:doi/10.1080%2F15384101.2020.1839701&rft_id=info%3Apmid%2F33131409&rft.externalDocID=33131409 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1538-4101&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1538-4101&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1538-4101&client=summon |